BRPI0906936A2 - Uso de canabinóide canabidiol e canabinóide tetraidrocanabivarina - Google Patents
Uso de canabinóide canabidiol e canabinóide tetraidrocanabivarinaInfo
- Publication number
- BRPI0906936A2 BRPI0906936A2 BRPI0906936-4A BRPI0906936A BRPI0906936A2 BR PI0906936 A2 BRPI0906936 A2 BR PI0906936A2 BR PI0906936 A BRPI0906936 A BR PI0906936A BR PI0906936 A2 BRPI0906936 A2 BR PI0906936A2
- Authority
- BR
- Brazil
- Prior art keywords
- cannabinoid
- tetrahydrocannabivarine
- cannabidiol
- cannabinoid use
- use cannabidiol
- Prior art date
Links
- 229930003827 cannabinoid Natural products 0.000 title 2
- 239000003557 cannabinoid Substances 0.000 title 2
- QHMBSVQNZZTUGM-UHFFFAOYSA-N Trans-Cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-UHFFFAOYSA-N 0.000 title 1
- QHMBSVQNZZTUGM-ZWKOTPCHSA-N cannabidiol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 title 1
- 229950011318 cannabidiol Drugs 0.000 title 1
- ZTGXAWYVTLUPDT-UHFFFAOYSA-N cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CC=C(C)C1 ZTGXAWYVTLUPDT-UHFFFAOYSA-N 0.000 title 1
- PCXRACLQFPRCBB-ZWKOTPCHSA-N dihydrocannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)C)CCC(C)=C1 PCXRACLQFPRCBB-ZWKOTPCHSA-N 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
- C07C39/23—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic, containing six-membered aromatic rings and other rings, with unsaturation outside the aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/78—Ring systems having three or more relevant rings
- C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pyrane Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0801051.4A GB2459637B (en) | 2008-01-21 | 2008-01-21 | New use for cannabinoids |
| PCT/GB2009/000159 WO2009093018A1 (en) | 2008-01-21 | 2009-01-21 | New use for cannabinoids |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0906936A2 true BRPI0906936A2 (pt) | 2015-07-28 |
Family
ID=39166091
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0906936-4A BRPI0906936A2 (pt) | 2008-01-21 | 2009-01-21 | Uso de canabinóide canabidiol e canabinóide tetraidrocanabivarina |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20110082195A1 (pt) |
| EP (1) | EP2254565A1 (pt) |
| JP (2) | JP2011509989A (pt) |
| CN (1) | CN101977596A (pt) |
| BR (1) | BRPI0906936A2 (pt) |
| CA (1) | CA2711873A1 (pt) |
| GB (1) | GB2459637B (pt) |
| WO (1) | WO2009093018A1 (pt) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0425248D0 (en) | 2004-11-16 | 2004-12-15 | Gw Pharma Ltd | New use for cannabinoid |
| EP1811983B1 (en) | 2004-11-16 | 2020-10-07 | GW Pharma Limited | New use for cannabinoid |
| GB2471523A (en) | 2009-07-03 | 2011-01-05 | Gw Pharma Ltd | Use of tetrahydrocannibivarin (THCV) and optionally cannabidiol (CBD) in the treatment of epilepsy |
| TWI583374B (zh) | 2010-03-30 | 2017-05-21 | Ｇｗ伐瑪有限公司 | 使用植物大麻素次大麻二酚（ｃｂｄｖ）來治療癲癇之用途 |
| US8445034B1 (en) | 2010-11-02 | 2013-05-21 | Albert L Coles, Jr. | Systems and methods for producing organic cannabis tincture |
| CA2726085A1 (en) * | 2010-12-20 | 2012-06-20 | Bernard Le Foll | User of marihuana and compounds therein for treating obesity |
| GB2514054A (en) | 2011-09-29 | 2014-11-12 | Gw Pharma Ltd | A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD) |
| GB2496687A (en) * | 2011-11-21 | 2013-05-22 | Gw Pharma Ltd | Tetrahydrocannabivarin (THCV) in the protection of pancreatic islet cells |
| US9259449B2 (en) * | 2014-01-07 | 2016-02-16 | Joshua Michael Raderman | Method for modifying THC content in a lipid-based extract of cannabis |
| US9380813B2 (en) | 2014-02-11 | 2016-07-05 | Timothy McCullough | Drug delivery system and method |
| US10821240B2 (en) | 2014-02-11 | 2020-11-03 | Vapor Cartridge Technology Llc | Methods and drug delivery devices using cannabis |
| US9220294B2 (en) | 2014-02-11 | 2015-12-29 | Timothy McCullough | Methods and devices using cannabis vapors |
| GB2530001B (en) | 2014-06-17 | 2019-01-16 | Gw Pharma Ltd | Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy |
| GB2527591A (en) | 2014-06-27 | 2015-12-30 | Gw Pharma Ltd | 7-hydroxy cannabidiol (7-OH-CBD) for use in the treatment of non-alcoholic fatty liver disease (NAFLD) |
| GB2527590A (en) * | 2014-06-27 | 2015-12-30 | Otsuka Pharma Co Ltd | Active pharmaceutical ingredient (API) comprising cannabinoids for use in the treatment of cancer |
| GB2527599A (en) | 2014-06-27 | 2015-12-30 | Gw Pharma Ltd | Use of 7-OH-Cannabidiol (7-OH-CBD) and/or 7-OH-Cannabidivarin (7-OH-CBDV) in the treatment of epilepsy |
| GB2531282A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB2531278A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabidiol in the treatment of intractable epilepsy |
| GB2531281A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabidiol in the treatment of intractable epilepsy |
| US9539295B2 (en) | 2014-12-05 | 2017-01-10 | Bradley Michael Bohus | Cannabidiol (CBD) enriched alcohol |
| GB2539472A (en) | 2015-06-17 | 2016-12-21 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
| BR112018001310A2 (pt) * | 2015-07-22 | 2018-09-11 | Phytopharma Int Ltd | composições ingeríveis por abelha, métodos de uso das mesmas para a produção de mel e mel produzido por estas |
| GB2541191A (en) | 2015-08-10 | 2017-02-15 | Gw Pharma Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB2548873B (en) | 2016-03-31 | 2020-12-02 | Gw Res Ltd | Use of Cannabidiol in the Treatment of SturgeWeber Syndrome |
| US10499584B2 (en) | 2016-05-27 | 2019-12-10 | New West Genetics | Industrial hemp Cannabis cultivars and seeds with stable cannabinoid profiles |
| GB2551987A (en) | 2016-07-01 | 2018-01-10 | Gw Res Ltd | Oral cannabinoid formulations |
| GB2551986A (en) | 2016-07-01 | 2018-01-10 | Gw Res Ltd | Parenteral formulations |
| TWI753930B (zh) | 2016-08-01 | 2022-02-01 | 德商矢倫德國股份有限公司 | 鏈條封閉鏈結 |
| GB2553139A (en) | 2016-08-25 | 2018-02-28 | Gw Res Ltd | Use of cannabinoids in the treatment of multiple myeloma |
| US10835501B2 (en) | 2016-10-01 | 2020-11-17 | Indication Bioscience Llc | Pharmaceutical compositions comprising a statin and a cannabinoid and uses thereof |
| GB2557921A (en) | 2016-12-16 | 2018-07-04 | Gw Res Ltd | Use of cannabinoids in the treatment of angelman syndrome |
| GB2559774B (en) | 2017-02-17 | 2021-09-29 | Gw Res Ltd | Oral cannabinoid formulations |
| EP3697409A4 (en) * | 2017-10-18 | 2021-06-02 | Mor Research Applications Ltd. | CANNABIDIOL AND CHITOSAN COMPOSITIONS AND METHOD OF USE THEREOF |
| GB2569961B (en) | 2018-01-03 | 2021-12-22 | Gw Res Ltd | Pharmaceutical |
| GB201806953D0 (en) | 2018-04-27 | 2018-06-13 | Gw Res Ltd | Cannabidiol Preparations |
| JP7344422B2 (ja) * | 2018-06-07 | 2023-09-14 | 漢義生物科技（北京）有限公司 | 糖尿病予防・治療用の医薬品組成物及びその用途 |
| CN110575447B (zh) * | 2018-06-07 | 2022-11-29 | 汉义生物科技（北京）有限公司 | 一种用于防治糖尿病的药物组合物及其用途 |
| WO2020028992A1 (en) * | 2018-08-08 | 2020-02-13 | Neptune Wellness Solutions Inc. | Cold extraction method for cannabinoids and terpenes from cannabis by organic solvents |
| AU2019335372A1 (en) * | 2018-09-05 | 2021-05-06 | Purisys Llc | Cannabidiol compositions having modified cannabinoid profiles |
| WO2020240550A1 (en) * | 2019-05-28 | 2020-12-03 | Bol Pharma Ltd. | Cannabidiol for treating type 1 diabetes mellitus |
| MX2022003189A (es) | 2019-09-16 | 2022-06-08 | Vapor Cartridge Tech Llc | Sistema de administración de fármacos con sustratos apilables. |
| JP2021061789A (ja) * | 2019-10-15 | 2021-04-22 | サムライ金沢株式会社 | 食品組成物および飼料組成物 |
| KR102448514B1 (ko) * | 2019-12-10 | 2022-10-05 | 한국 한의학 연구원 | 대마 줄기 추출물을 유효성분으로 함유하는 동맥경화의 예방, 개선 또는 치료용 조성물 |
| IL272078A (en) | 2020-01-16 | 2021-07-29 | Can Fite Biopharma Ltd | Cannabinoids for use in therapy |
| GB202002754D0 (en) | 2020-02-27 | 2020-04-15 | Gw Res Ltd | Methods of treating tuberous sclerosis complex with cannabidiol and everolimus |
| KR102393417B1 (ko) * | 2020-06-04 | 2022-05-02 | 재단법인 경북바이오산업연구원 | 대마 줄기 추출물을 포함하는 항당뇨용 조성물 |
| KR102393416B1 (ko) * | 2020-06-04 | 2022-05-02 | 재단법인 경북바이오산업연구원 | 대마 뿌리 추출물을 포함하는 항당뇨용 조성물 |
| KR20210158175A (ko) * | 2020-06-23 | 2021-12-30 | 주식회사 유셀파마 | 대마 줄기 추출물을 유효성분으로 함유하는 고콜레스테롤혈증의 예방, 개선 또는 치료용 조성물 |
| EP4188090A2 (en) | 2020-07-28 | 2023-06-07 | Impello Biosciences, Inc. | Methods and compositions for altering secondary metabolites in plants |
| US11160757B1 (en) | 2020-10-12 | 2021-11-02 | GW Research Limited | pH dependent release coated microparticle cannabinoid formulations |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2381194A (en) * | 2001-09-07 | 2003-04-30 | Gw Pharmaceuticals Ltd | Pharmaceutical formulations |
| IL160420A0 (en) * | 2004-02-16 | 2004-07-25 | Yissum Res Dev Co | Treating or preventing diabetes with cannabidiol |
| GB2414933B (en) * | 2004-06-08 | 2009-07-15 | Gw Pharma Ltd | Cannabinoid compositions for the treatment of disease and/or symptoms in arthritis |
| EP1811983B1 (en) * | 2004-11-16 | 2020-10-07 | GW Pharma Limited | New use for cannabinoid |
| GB0425248D0 (en) * | 2004-11-16 | 2004-12-15 | Gw Pharma Ltd | New use for cannabinoid |
| WO2007032962A2 (en) * | 2005-09-09 | 2007-03-22 | University Of Kentucky | Compositions and methods for intranasal delivery of tricyclic cannabinoids |
| WO2007105210A2 (en) * | 2006-03-13 | 2007-09-20 | Hadasit Medical Research Services & Development Limited | Therapeutic uses of cannabidiol compounds |
| GB2438682A (en) * | 2006-06-01 | 2007-12-05 | Gw Pharma Ltd | New use for cannabinoids |
| EP2068853A2 (en) * | 2006-09-15 | 2009-06-17 | Stevia APS | Treatment of insulin resistance or diseases associated with insulin resistance with bicyclo[3.2.1]octans such as steviol and isosteviol |
| GB2450753B (en) * | 2007-07-06 | 2012-07-18 | Gw Pharma Ltd | New Pharmaceutical formulation |
| GB2456183A (en) * | 2008-01-04 | 2009-07-08 | Gw Pharma Ltd | Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament |
-
2008
- 2008-01-21 GB GB0801051.4A patent/GB2459637B/en active Active
-
2009
- 2009-01-21 BR BRPI0906936-4A patent/BRPI0906936A2/pt not_active IP Right Cessation
- 2009-01-21 CN CN2009801103479A patent/CN101977596A/zh active Pending
- 2009-01-21 US US12/863,842 patent/US20110082195A1/en not_active Abandoned
- 2009-01-21 CA CA2711873A patent/CA2711873A1/en not_active Abandoned
- 2009-01-21 JP JP2010542690A patent/JP2011509989A/ja active Pending
- 2009-01-21 EP EP09704918A patent/EP2254565A1/en not_active Withdrawn
- 2009-01-21 WO PCT/GB2009/000159 patent/WO2009093018A1/en active Application Filing
-
2013
- 2013-01-07 US US13/735,108 patent/US20130245110A1/en not_active Abandoned
-
2015
- 2015-02-20 JP JP2015032025A patent/JP2015120739A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20130245110A1 (en) | 2013-09-19 |
| GB0801051D0 (en) | 2008-02-27 |
| GB2459637A (en) | 2009-11-04 |
| JP2015120739A (ja) | 2015-07-02 |
| US20110082195A1 (en) | 2011-04-07 |
| EP2254565A1 (en) | 2010-12-01 |
| GB2459637B (en) | 2012-06-06 |
| CA2711873A1 (en) | 2009-07-30 |
| JP2011509989A (ja) | 2011-03-31 |
| CN101977596A (zh) | 2011-02-16 |
| WO2009093018A1 (en) | 2009-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0906936A2 (pt) | Uso de canabinóide canabidiol e canabinóide tetraidrocanabivarina | |
| BRPI0915086A2 (pt) | detecção do uso de canabis | |
| BRPI0821668A2 (pt) | Uso | |
| BRPI0821276A2 (pt) | Produto, e, uso do produto | |
| BR112012002349A2 (pt) | composto,e, uso do mesmo | |
| BRPI0919193A2 (pt) | Uso de lipídeo, e, composição nutricional | |
| BRPI1012533A2 (pt) | composto de piradazinona e uso do mesmo | |
| BRPI0907231A2 (pt) | pirrolpirimidinas e pirrolpiridinas | |
| DOP2010000260A (es) | Derivado heterociclico fusionado y su uso | |
| BRPI0906478A2 (pt) | anticorpo anti-nr10 e uso do mesmo | |
| BR112012003792A2 (pt) | gel tópico, e, uso do gel tópico. | |
| BRPI0823082A2 (pt) | Uso derivados de sesquiterpeno | |
| BRPI0907453A2 (pt) | Compostos, uso e preparação dos mesmos | |
| BRPI1010024A2 (pt) | derivados de aminopirrolidinona e uso dos mesmos | |
| BRPI0813627A2 (pt) | Peptídio antimicrobiano, composições e métodos de uso | |
| BRPI0822296A2 (pt) | Transponder e livreto | |
| BRPI0716327A2 (pt) | Composto de fenilpropionamida e uso | |
| BRPI1007494A2 (pt) | composto e uso do mesmo | |
| BRPI0907365A2 (pt) | Composição antimicrobiana e uso | |
| SMT201500218B (it) | Composti aril-fenil-solfonammido-cicloalchile e loro uso | |
| BRPI0920953A2 (pt) | dispositivo de manutenção, e uso do mesmo. | |
| BRPI0919794A2 (pt) | dispositivo para uso intracorpóreo, e, composto | |
| BRPI0919216A2 (pt) | poliuretano, e, uso de um poliuretano | |
| BRPI0818641A2 (pt) | Rótulo, e, uso do rótulo | |
| BRPI0903906A2 (pt) | Dispositivo de iluminação, e, unidade de mostrador |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07F | Notification of approval that there is no relation to art. 229 of lpi (pipeline patents) [chapter 7.6 patent gazette] |
Free format text: NOTIFICACAO DE NAO ANUENCIA RELACIONADA COM O ART. 229 DA LPI |
|
| B11R | Patent application dismissed according to article 229 of the patent law [chapter 11.18 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 11A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2550 DE 19-11-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |